Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 213-219

  Fadini, Gian Paolo ^a   de Kreutzenberg, Saula ^a   Agostini, Carlo ^a   Boscaro, Elisa ^a   Tiengo, Antonio ^a   Dimmeler, Stefanie ^b   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Cardiovascular risk; Endothelium; Metabolic syndrome; Stem cells

Indexed keywords

C REACTIVE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVERSE OUTCOME; ANTIGEN EXPRESSION; ARTICLE; CD34 SELECTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STEM CELL;

ANTIGENS, CD; ANTIGENS, CD34; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL COUNT; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; STEM CELLS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70350554692     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.040     Document Type: Article

References (40)

1. Avogaro P., Crepaldi G., Enzi G., and Tiengo A. Association of hyperlipidemia, diabetes mellitus and moderate obesity. Acta Diabetol Lat 4 (1967) 572-590
2. Grundy S., Cleeman J., Daniels S., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
3. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes 28 (2005) 2289-2304
4. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
5. Gami A.S., Witt B.J., Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49 (2007) 403-414
6. Neels J.G., and Olefsky J.M. Inflamed fat: what starts the fire?. J Clin Invest 116 (2006) 33-35
7. Fadini G.P., Coracina A., Inchiostro S., et al. A stepwise approach to assess the impact of clustering cardiometabolic risk factors on carotid intima-media thickness: the metabolic syndrome no-more-than-additive. Eur J Cardiovasc Prev Rehabil 15 (2008) 190-196
8. Lteif A.A., Han K., and Mather K.J. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112 (2005) 32-38
9. Kim J.A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
10. Urbich C., and Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95 (2004) 343-353
11. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 (1999) 434-438
12. Hristov M., Erl W., and Weber P.C. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 23 (2003) 1185-1189
13. Fadini G.P., Baesso I., Albiero M., et al. Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 197 (2008) 496-503
14. Friedrich E.B., Walenta K., Scharlau J., et al. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 98 (2006) e20-25
15. Fadini G.P., Agostini C., Sartore S., and Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194 (2007) 46-54
16. Fadini G.P., Coracina A., Baesso I., et al. Peripheral blood CD34 + KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 37 (2006) 2277-2282
17. Fadini G.P., Sartore S., Albiero M., et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26 (2006) 2140-2146
18. Schmidt-Lucke C., Rossig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005) 2981-2987
19. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
20. Werner N., and Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?. Arterioscler Thromb Vasc Biol 26 (2006) 257-266
21. Fadini G.P., Miorin M., Facco M., et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45 (2005) 1449-1457
22. Fadini G.P., de Kreutzenberg S.V., Coracina A., et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J 27 (2006) 2247-2255
23. Wilson P., D'Agostino R., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
24. Ferrario M., Chiodini P., Chambless L.E., et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol 34 (2005) 413-421
25. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
26. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
27. Novo G., Corrado E., Muratori I., et al. Markers of inflammation and prevalence of vascular disease in patients with metabolic syndrome. Int Angiol 26 (2007) 312-317
28. Levey A.S., Bosch J.P., Lewis J.B., et al. More accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
29. Schoenfeld D.A., and Richter J.R. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38 (1982) 163-170
30. Rothman K.J. The estimation of synergy or antagonism. Am J Epidemiol 103 (1976) 506-511
31. Zou G.Y. On the estimation of additive interaction by use of the four-by-two table and beyond. Am J Epidemiol 168 (2008) 212-224
32. Marshall S.W. Power for tests of interaction: effect of raising the type I error rate. Epidemiol Perspect Innov 4 (2007) 4
33. Yeh E., Zhang S., Wu H., et al. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108 (2003) 2070-2073
34. Krause D., Theise N., Collector M., et al. Multi-organ multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105 (2001) 369-377
35. Wojakowski W., Tendera M., Michalowska A., et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110 (2004) 3213-3220
36. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., and Stern M.P. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
37. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults. Circulation (2004) 1245-1250
38. Bruno G., Merletti F., Biggeri A., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27 (2004) 2689-2694
39. Inchiostro S., Fadini G.P., de Kreutzenberg S.V., Citroni N., and Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components?. J Am Coll Cardiol 49 (2007) 2465
40. Fadini G.P., Agostini C., Boscaro E., and Avogaro A. Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. Metab Syndr Relat Disord 7 (2009) 5-10